Royal Bank Of Canada Cuts Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price target reduced by Royal Bank Of Canada from $18.00 to $14.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

CATX has been the topic of a number of other reports. UBS Group reissued a “buy” rating and set a $7.00 target price (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. Piper Sandler started coverage on shares of Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective for the company. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Monday, November 24th. They set a “buy” rating and a $12.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Friday, January 30th. Finally, BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Down 5.3%

Shares of NYSEAMERICAN CATX opened at $4.60 on Tuesday. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The business has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. The firm had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. Analysts expect that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth $61,000. Geode Capital Management LLC increased its holdings in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after purchasing an additional 188,887 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares during the period. Walleye Capital LLC raised its stake in shares of Perspective Therapeutics by 375.8% during the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after purchasing an additional 60,019 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Several major firms raised ratings or price targets, which supports upside sentiment: B. Riley raised its price target to $13 and kept a Buy rating (large implied upside). UBS increased its target to $8 with a Buy. Wedbush reaffirmed an Outperform and a $11 target. Article Title
• Positive Sentiment: BTIG issued a Buy rating, adding to the cluster of bullish research that can attract momentum investors and buyers ahead of earnings. Article Title
• Positive Sentiment: Brookline Capital Markets (analyst K. Dolliver) raised EPS forecasts across Q1–Q4 2026 and lifted FY2026 from ($1.98) to ($1.27) — a meaningful reduction in projected losses vs their prior view. Incremental beat/less-bad guidance in analyst models tends to be supportive for the stock. Note Brookline’s FY view still implies a loss below consensus. Article Title
• Neutral Sentiment: Perspective announced a quarterly earnings release date (upcoming). Earnings will likely be the primary near-term catalyst and could swing the stock either way depending on clinical/program updates, cash burn, or guidance. Article Title
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX’s stock price, which may pressure sentiment among investors who follow bank research or use RBC’s view for risk management. Article Title

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.